DE69528714T2 - Propofol und disodium edta enthaltende öl-in-wasser emulsionen - Google Patents

Propofol und disodium edta enthaltende öl-in-wasser emulsionen

Info

Publication number
DE69528714T2
DE69528714T2 DE69528714T DE69528714T DE69528714T2 DE 69528714 T2 DE69528714 T2 DE 69528714T2 DE 69528714 T DE69528714 T DE 69528714T DE 69528714 T DE69528714 T DE 69528714T DE 69528714 T2 DE69528714 T2 DE 69528714T2
Authority
DE
Germany
Prior art keywords
propofol
water emulsions
containing oil
disodium edta
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528714T
Other languages
English (en)
Other versions
DE69528714D1 (de
Inventor
Christopher Buchan Jones
John Henry Platt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48793621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69528714(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69528714D1 publication Critical patent/DE69528714D1/de
Publication of DE69528714T2 publication Critical patent/DE69528714T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69528714T 1994-03-22 1995-03-17 Propofol und disodium edta enthaltende öl-in-wasser emulsionen Expired - Lifetime DE69528714T2 (de)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GB9405593A GB9405593D0 (en) 1994-03-22 1994-03-22 Pharmaceutical compositions
NZ282005A NZ282005A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol (2,6 diisopropylphenol) and edetate
BR9510452A BR9510452A (pt) 1994-03-22 1995-03-17 Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos
CH01282/04A CH694423A5 (de) 1994-03-22 1995-03-17 Verwendung von Edetat zur Stabilisierung von pharmzeutischen Zusammensetzungen.
PCT/GB1995/000579 WO1996029064A1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
NZ500588A NZ500588A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate for producing anaesthesia
BE9500241A BE1009198A5 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol.
DE19509828A DE19509828A1 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzungen
PL95322278A PL186354B1 (pl) 1994-03-22 1995-03-17 Jałowe kompozycje farmaceutyczne oraz sposoby ograniczania potencjału wzrostowego drobnoustrojów i poprawiania czasu stosowania emulsji
CA002212794A CA2212794C (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
EP95911412A EP0814787B1 (de) 1994-03-22 1995-03-17 Propofol und disodium edta enthaltende öl-in-wasser emulsionen
HU9702180A HU227951B1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and disodium edetate
FR9503128A FR2731617B1 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol
CH02011/97A CH693764A5 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat.
CH00393/03A CH693762A5 (de) 1994-03-22 1995-03-17 Wässrige Zusammensetzungen enthaltend eine Öl-in-Wasser-Emulsion
ZA952239A ZA952239B (en) 1994-03-22 1995-03-17 Pharmaceutical compositions
NO19974278A NO320007B1 (no) 1994-03-22 1997-09-16 Steril farmasoytisk blanding inneholdende propofol og edetat for parenteral administrering, fremgangsmate for a begrense potensialet for mikrobevekst i blandingen, samt anvendelse derav.
JP00624199A JP4012328B2 (ja) 1994-03-22 1999-01-13 エデテートを含有する水中油滴エマルジョン
FI20085586A FI120641B (fi) 1994-03-22 2008-06-13 Ruuansulatuskanavan ulkopuolisesti annettavat rasvaemulsiot, jotka sisältävät edetaattia säilöntäaineena

Publications (2)

Publication Number Publication Date
DE69528714D1 DE69528714D1 (de) 2002-12-05
DE69528714T2 true DE69528714T2 (de) 2003-06-12

Family

ID=48793621

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69528714T Expired - Lifetime DE69528714T2 (de) 1994-03-22 1995-03-17 Propofol und disodium edta enthaltende öl-in-wasser emulsionen
DE19509828A Ceased DE19509828A1 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19509828A Ceased DE19509828A1 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzungen

Country Status (33)

Country Link
US (1) US5714520A (de)
EP (2) EP1238677B1 (de)
JP (2) JP3067806B2 (de)
AT (2) ATE312625T1 (de)
AU (1) AU710143B2 (de)
BE (1) BE1009198A5 (de)
BR (1) BR9510452A (de)
CA (1) CA2212794C (de)
CH (4) CH694423A5 (de)
CZ (1) CZ297549B6 (de)
DE (2) DE69528714T2 (de)
DK (3) DK1238677T3 (de)
ES (2) ES2183869T3 (de)
FI (2) FI120640B (de)
FR (1) FR2731617B1 (de)
GB (2) GB9405593D0 (de)
HK (1) HK1008927A1 (de)
HU (1) HU227951B1 (de)
IL (1) IL113021A (de)
IT (1) IT1281193B1 (de)
LU (1) LU90136B1 (de)
MX (1) MX9707005A (de)
NO (2) NO320007B1 (de)
NZ (2) NZ282005A (de)
PL (1) PL186354B1 (de)
PT (1) PT814787E (de)
RU (1) RU2147432C1 (de)
SE (2) SE523909C2 (de)
SI (1) SI0814787T1 (de)
SK (1) SK286375B6 (de)
TW (1) TW458781B (de)
WO (1) WO1996029064A1 (de)
ZA (1) ZA952239B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
KR19980025601A (ko) * 1996-10-04 1998-07-15 우동일 혈관주사제용 프로포폴 유탁액의 제조방법
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
ATE370726T1 (de) 1998-02-10 2007-09-15 Sicor Inc Propofolhaltiges arzneimittel enthaltend sulfite
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
DK1105096T3 (da) * 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
ATE283042T1 (de) * 1999-01-28 2004-12-15 Dinesh Shantilal Patel Parenterale lösungen enthaltend propofol (2,6- diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6- dianhydro-d-glucitol als lösungsmittel
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
JP2003502363A (ja) * 1999-06-21 2003-01-21 コンイル ファーマシューティカル カンパニー、リミテッド プロポフォールを含有する静脈内注射用麻酔剤組成物
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
KR20030007686A (ko) * 2000-05-25 2003-01-23 아스트라제네카 아베 유리-래디칼 제거 진정제 및 금속이온 킬레이트화제를함유하는 약제학적 조성물
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
CA2412905A1 (en) * 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
IN188917B (de) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
WO2002092082A1 (en) 2001-05-11 2002-11-21 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US8541472B2 (en) 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
PL207038B1 (pl) 2002-01-25 2010-10-29 Theravance Podstawione pochodne kwasu fenylooctowego, związek pośredni, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
NZ535484A (en) * 2002-04-08 2009-01-31 Mgi Gp Inc Pharmaceutical compositions containing fospropofol (O-phosphonooxymethylpropofol) and methods of administering same
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
JP2005538191A (ja) 2002-07-29 2005-12-15 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 水性2,6―ジイソプロピルフェノール医薬組成物
CA2503956A1 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7790766B2 (en) * 2003-07-23 2010-09-07 Theravance, Inc. Pharmaceutical compositions of short-acting sedative hypnotic agent
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
EP1680409A4 (de) * 2003-10-24 2007-12-05 Auspex Pharmaceuticals Inc Ph-wert-empfindliche prodrugs von 2,6-diisopropylphenol
KR20070005617A (ko) 2004-02-13 2007-01-10 바이오어베일러빌리티, 아이엔씨. 마취용 고농도 프로포폴 마이크로에멀젼 조제물
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1850829A4 (de) * 2005-02-03 2012-12-26 Taro Pharmaceuticals Usa Inc Neue propofolzusammensetzung mit ascorbinsäure oder pharmazeutisch nutzbaren salzen davon
CN101184481A (zh) 2005-02-18 2008-05-21 阿布拉西斯生物科学公司 用于局部缺血性损伤的2,6-二异丙基苯酚和类似物的组合物,其使用和制备方法
WO2006128088A1 (en) * 2005-05-27 2006-11-30 Sandhya Goyal Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
ATE420625T1 (de) * 2005-08-05 2009-01-15 Bharat Serums & Vaccines Ltd Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt
EP1928412B1 (de) * 2005-08-12 2015-09-16 Bharat Serums & Vaccines Ltd. Wässrige narkosezusammensetzungen mit propofol
US20080234229A1 (en) * 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
SI3311805T1 (sl) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
EP1928435B8 (de) * 2005-08-31 2019-03-20 Abraxis BioScience, LLC Zusammensetzungen von schwer wasserlöslichen arzneimitteln mit erhöhter stabilität und verfahren zu deren herstellung
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN1903187B (zh) * 2006-03-21 2012-05-30 沈阳药科大学 含有局麻药的复方异丙酚注射剂及制备工艺
WO2008141097A2 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds
JP2010526827A (ja) * 2007-05-09 2010-08-05 ファーマコフォア,インク. 治療用化合物
KR20080102010A (ko) * 2007-05-17 2008-11-24 대원제약주식회사 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
CA3108961A1 (en) 2008-08-01 2010-02-04 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
WO2010082092A1 (en) 2009-01-13 2010-07-22 Claris Lifesciences Limited Propofol based anesthetic with preservative
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
EP2627173B2 (de) * 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipin-emulsionsformulierungen mit antimikrobiellen mitteln
CN102407986B (zh) * 2011-11-03 2013-11-27 南通四方冷链装备股份有限公司 隔料装置
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
CN102579555A (zh) * 2012-03-01 2012-07-18 四川大学华西医院 注射用脂肪乳在作为拮抗全身麻醉用药作用的药物制备中的应用
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
US11357743B2 (en) 2017-04-19 2022-06-14 Mayo Foundation For Medical Education And Research Ketamine and propofol admixture

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3384545A (en) * 1965-03-09 1968-05-21 Hoffmann La Roche Injectable aqueous emulsions of fat soluble vitamins
US3230143A (en) * 1965-05-14 1966-01-18 Merck & Co Inc Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
DE1792410B2 (de) * 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Arzneimittelzubereitung zur intravenösen Injektion
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS5916818A (ja) * 1982-07-20 1984-01-28 Shimizu Seiyaku Kk 経静脈投与用輸液剤
SE8505047L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Fettemulsion
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4868169A (en) * 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steroid cream formulation
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
WO1990006055A1 (en) * 1988-11-29 1990-06-14 Unilever Plc Antimicrobial agents and uses thereof
GB8828517D0 (en) * 1988-12-07 1989-01-11 Leopold & Co Ag Stable emulsions
US5079003A (en) * 1990-03-14 1992-01-07 Adelia Scaffidi Skin lotions and creams
JP3308555B2 (ja) * 1991-03-08 2002-07-29 カネボウ株式会社 微細化エマルション組成物の製造方法
JP2811036B2 (ja) * 1992-05-26 1998-10-15 参天製薬株式会社 ビタミンe点眼剤
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ITMI950529A1 (it) 1996-09-17
JPH11500737A (ja) 1999-01-19
EP1238677A2 (de) 2002-09-11
GB2298789A (en) 1996-09-18
IL113021A0 (en) 1995-12-08
PL322278A1 (en) 1998-01-19
DK106697A (da) 1997-09-17
FI120640B (fi) 2010-01-15
SE523909C2 (sv) 2004-06-01
GB9505405D0 (en) 1995-05-03
US5714520A (en) 1998-02-03
NO334956B1 (no) 2014-08-04
ES2253469T3 (es) 2006-06-01
FI973702A0 (fi) 1997-09-16
FI973702A (fi) 1997-09-16
HU227951B1 (en) 2012-07-30
SE9703274L (sv) 1997-09-10
AU710143B2 (en) 1999-09-16
SI0814787T1 (en) 2003-04-30
CH693762A5 (de) 2004-01-30
SE0400115D0 (sv) 2004-01-21
JPH11263725A (ja) 1999-09-28
NO320007B1 (no) 2005-10-10
PT814787E (pt) 2003-02-28
BE1009198A5 (fr) 1996-12-03
ITMI950529A0 (it) 1995-03-17
IT1281193B1 (it) 1998-02-17
CA2212794A1 (en) 1996-09-26
CZ290497A3 (en) 1997-12-17
ZA952239B (en) 1996-09-17
EP1238677B1 (de) 2005-12-14
IL113021A (en) 2001-04-30
NO20041838L (no) 1997-09-16
HK1008927A1 (en) 1999-07-16
GB2298789B (en) 1999-12-08
CH693764A5 (de) 2004-01-30
MX9707005A (es) 1997-11-29
NZ500588A (en) 2001-04-27
FI120641B (fi) 2010-01-15
NO974278L (no) 1997-09-16
ES2183869T3 (es) 2003-04-01
SE9703274D0 (sv) 1997-09-10
FR2731617B1 (fr) 1997-05-30
RU2147432C1 (ru) 2000-04-20
PL186354B1 (pl) 2003-12-31
JP3067806B2 (ja) 2000-07-24
FI20085586A (fi) 2008-06-13
CA2212794C (en) 2000-09-12
WO1996029064A1 (en) 1996-09-26
NZ282005A (en) 2000-01-28
ATE226817T1 (de) 2002-11-15
CZ297549B6 (cs) 2007-02-07
EP0814787B1 (de) 2002-10-30
BR9510452A (pt) 1998-05-19
CH694423A5 (de) 2005-01-14
CH694396A5 (de) 2004-12-31
GB9405593D0 (en) 1994-05-11
TW458781B (en) 2001-10-11
DK0814787T3 (da) 2003-01-06
AU1898895A (en) 1996-10-08
SK286375B6 (sk) 2008-08-05
SE0400115L (sv) 2004-01-21
LU90136B1 (de) 1997-11-27
NO974278D0 (no) 1997-09-16
SK124797A3 (en) 1998-01-14
SE527123C2 (sv) 2005-12-27
FR2731617A1 (fr) 1996-09-20
DK1238677T3 (da) 2006-03-06
JP4012328B2 (ja) 2007-11-21
ATE312625T1 (de) 2005-12-15
EP0814787A1 (de) 1998-01-07
HUT77358A (hu) 1998-03-30
EP1238677A3 (de) 2003-01-22
DE19509828A1 (de) 1996-09-19
DE69528714D1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
DE69528714T2 (de) Propofol und disodium edta enthaltende öl-in-wasser emulsionen
IL114212A (en) Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE69016749D1 (de) Emulsion.
DE69011922D1 (de) Arzneiemulsionen.
GR3024405T3 (en) Preparations comprising a fluorocarbon and a lipophilic/fluorophilic organic compound, and their use
DE69625213T2 (de) Mikroemulsionen zur verwendung als träger zur verabreichung von wirkstoffen
ES431706A1 (es) Un procedimiento de preparacion de emulsiones de compuestosfluorados en agua o en soluciones salinas.
KR870002835A (ko) 이온화성 소수성약제의 약제학적 제조방법
ES2114931T3 (es) Nuevos esteres esteroidales.
ES2053897T3 (es) Un metodo para estabilizar factores de coagulacion de la sangre.
MX9300674A (es) Biorreactor de hepatocitos, metodo para hacerlo, metodo para usarlos y sistema de asistencia para el mismo.
SE8705064D0 (sv) Emulsion for parenteral administrering
KR940008678A (ko) 주사용 메스나 액제
ES2084657T3 (es) Agente para el tratamiento de los trastornos del sistema de transmision cerebro-neural.
BR0111094A (pt) Composição farmacêutica, uso de uma composição farmacêutica estéril, e, método para melhorar a sobrevida em um paciente criticamente doente

Legal Events

Date Code Title Description
8363 Opposition against the patent